MTOR and breast cancer: Furthermore, based on our previous study, which showed that MEDAG promotes EMT and reduces epirubicin sensitivity through the Akt/AMPK/mTOR axis in BC 9, we hypothesized that MEDAG is involved in HG-induced BC progression.